NEWS

New Trial Alert: Alliance A151804 Establishment of National Biorepository | Immune-related Side Effects

January 31, 2020

 

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events

Overview: Alliance investigator David Kozono, MD, PhD, of Dana-Farber/Brigham and Women's Hospital, leads this trial to collect research data and samples from patients who experience immunotherapy side effects to store for use in future


New Trial Alert: Alliance A031803 Non-muscle Invasive Bladder Cancer

January 6, 2020

Alliance A031803: Phase II trial of intravesical gemcitabine and MK-3475 (pembrolizumab) in the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer

Overview: Alliance investigator Michael Woods, MD, of Loyola University Medical Center, leads this phase II trial to see how well gemcitabine together with pembrolizumab works in treating patients with non-muscle invasive bl


New Trial: Alliance A031801 Advanced Renal Cell Cancer

December 16, 2019

Alliance A031801: A phase II randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma with bone metastasis (RadiCal)

Overview: Alliance investigator Rana R. McKay, MD, of the University of California San Diego, leads this phase II trial to see whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcome in patients with renal cel


Older News